Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-2965
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study ; volume:34 ; number:3 ; day:5 ; month:1 ; year:2023 ; pages:573-584 ; date:3.2023
Osteoporosis international ; 34, Heft 3 (5.1.2023), 573-584, 3.2023
- Creator
-
Tutaworn, Teerapat
Nieves, Jeri W.
Wang, Zhaorui
Levin, Justin E.
Yoo, Jae E.
Lane, Joseph M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00198-022-06648-9
- URN
-
urn:nbn:de:101:1-2023041221251653617835
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tutaworn, Teerapat
- Nieves, Jeri W.
- Wang, Zhaorui
- Levin, Justin E.
- Yoo, Jae E.
- Lane, Joseph M.
- SpringerLink (Online service)
Other Objects (12)
Observations following discontinuation of long-term denosumab therapy
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
Adherence to and persistence with zoledronic acid treatment for osteoporosis—reasons for early discontinuation
Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
Suicide prevented
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Denosumab and muscle performance
Denosumab: A comprehensive review
Observations following discontinuation of long-term denosumab therapy
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
Adherence to and persistence with zoledronic acid treatment for osteoporosis—reasons for early discontinuation
Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
Suicide prevented
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Denosumab and muscle performance
Denosumab: A comprehensive review
Observations following discontinuation of long-term denosumab therapy
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
Adherence to and persistence with zoledronic acid treatment for osteoporosis—reasons for early discontinuation
Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
Suicide prevented
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Denosumab and muscle performance